Unmasking social anxiety disorder

Journal of Psychiatry and Neuroscience

Volumn 26, Issue 3, 2001, Pages 185-189

  Stein, M B ^a   Gorman, J M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CLONAZEPAM; FLUVOXAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANXIETY NEUROSIS; BEHAVIOR THERAPY; CLINICAL FEATURE; COGNITIVE THERAPY; COMORBIDITY; FUNCTIONAL DISEASE; HEALTH CARE COST; HUMAN; NOTE; PATHOGENESIS; PREVALENCE; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; QUALITY OF LIFE;

COGNITIVE THERAPY; HUMANS; INTERPERSONAL RELATIONS; PHOBIC DISORDERS; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; SHYNESS;

EID: 0034976104     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (58)

1. Social phobia: Review of a neglected anxiety disorder
2. How shy is too shy?
3. Social phobia: Epidemiology, recognition, and treatment
4. Coming face-to-face with social phobia
5. Linking self-reported childhood behavioral inhibition to adolescent social phobia
6. Systematic assessment of 50 children with selective mutism
7. Psychopathology of childhood social phobia
8. Social phobia: Comorbidity and morbidity in an epidemiological sample
9. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey
10. Social phobia subtypes in the National Comorbidity Survey
11. Social fears and social phobia in a community sample of adolescents and young adults: Prevalence, risk factors and co-morbidity
12. Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia
13. Lifetime comorbidities between social phobia and mood disorders in the U.S. National Comorbidity Survey
14. Subtypes of social phobia and comorbidity with depression and other anxiety disorders
15. Patterns of Axis I comorbidity in early-onset versus late-onset major depressive disorder
16. The influence of anxiety as a risk to early onset major depression
17. Onset of psychopathology in offspring by developmental phase and parental depression
18. Social phobia in a population-based female adolescent twin sample: Co-morbidity and associated suicide-related symptoms
19. Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression?
20. Social anxiety disorder and the risk of depression: A prospective community study of adolescents and young adults
21. Social phobia: A comparative clinical study
22. Obsessive-compulsive and related disorders: A hidden epidemic
23. Increasing frequency of the diagnosis of obsessive-compulsive disorder
24. Lifetime prevalence of specific psychiatric disorders in three sites
25. Setting diagnostic thresholds for social phobia: Considerations from a community survey of social anxiety
26. One-year prevalence of psychiatric disorder in Ontarians 15 to 64 years of age
27. Classification and epidemiology of social phobia
28. Prevalence of mental disorders and psychosocial impairments in adolescents and young adults
29. Social phobia in the primary care medical setting
30. Social phobia in general health care: An unrecognized undertreated disabling disorder
31. Quality of life in individuals with anxiety disorders
32. The epidemiology of social phobia: Findings from the Duke Epidemiologic Catchment Area Study
33. Functional impairment in social phobia
34. The impact of social phobia on quality of life
35. Illness intrusiveness in individuals with panic disorder, obsessive-compulsive disorder, or social phobia
36. Quality of life in social phobia
37. Disability and quality of life in social phobia
38. Childhood shyness and maternal social phobia: A community study
39. Parental psychopathology, parenting styles and the risk of social phobia in offspring: A prospective-longitudinal community study
40. A direct-interview family study of generalized social phobia
41. Social phobia
42. Neurobiological perspectives on social phobia: From Affiliation to Zoology
43. Dopamine reuptake site densities in patients with social phobia
44. 2 receptor binding potential in social phobia
45. Delineating social phobia
46. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-Week outcome
47. Phenelzine vs atenolol in social phobia
48. Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine
49. Moclobemide in social phobia: A double-blind, placebo-controlled study
50. Moclobemide in social phobia: A controlled dose-response trial
51. Placebo-controlled trial of moclobemide in social phobia
52. Treatment of social phobia with clonazepam and placebo
53. Clinical effects of buspirone in social phobia: A double-blind placebo-controlled study
54. Paroxetine treatment of generalized social anxiety disorder (social phobia): A randomized controlled trial
55. Fluvoxamine in social phobia (social anxiety disorder): A double-blind, placebo-controlled clinical study
56. Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study
57. Social phobia. Epidemiology and cost of illness
58. Barriers to the treatment of social anxiety